Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Palomar’s home-use laser for wrinkle removal

This article was originally published in The Gray Sheet

Executive Summary

Palomar Medical Technologies gains 510(k) clearance June 5 for an over-the-counter, home-use laser for treatment of periorbital wrinkles - the first clearance of its kind, according to the company. The product will be marketed directly to consumers without a prescription by Johnson & Johnson under an existing agreement (1"The Gray Sheet" Sept. 13, 2004, p. 25). The device will enable laser wrinkle reduction "for a fraction of the cost" of similar treatments in the professional setting, according to Palomar

You may also be interested in...

J&J ends Palomar deal

Palomar says it will move forward with commercialization of its home-use, light-based technology for treatment of cellulite, skin aging and acne after Johnson & Johnson backed out of an agreement to market the product, citing economic conditions. The Burlington, Mass.-based firm received 510(k) clearance for the device for treatment of periorbital wrinkles in June (1"The Gray Sheet" June 15, 2009). Citing a multi-billion dollar market opportunity, Palomar CEO Joseph Caruso said the firm plans to launch the device for multiple applications in the second half of 2010. Near-term marketing efforts will focus on "certain specialty channels," Caruso said

J&J/Palomar Device Deal Aims To Bring Lasers To OTC Skin Care Market

Johnson & Johnson Consumer Companies is entering the aesthetic laser market through a partnership with Palomar Medical, announced Sept. 7

Surging China Coronavirus Trials Prompt Tougher Criteria

A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts